Introduction/aim Children with Prader-Willi syndrome (PWS) show alterations in infantile, childhood and pubertal growth. Growth Hormone (GH) therapy is recommended due to reported improvements in height velocity (HV) and body composition. The aim was to describe the patterns of growth in PWS and the influence of both changes in clinical practice and GH therapy. Methods Height SDS(HSDS), BMISDS and HVSDS of children attending a dedicated PWS clinic, 2000-2017, were analysed. To identify changes in growth we compared growth parameters between 2000-2012 and 2013-2017 . In 21 children who received GH(median age at GH start 4.92 years (2.27,8.1)), consecutive measurements were available at À1, 0,+1 and+2 years from GH start. Results Overall, 60 children(31 F/29 M) were included. Three phases of growth after the age of 1 year were identified: 1-5 years, with acceleration in both HSDS(r, 0.310, p,<0.0001) and BMISDS(r, 0.602, p,<0.0001); 6-12 years, with stabilisation in both HSDS(r, 0.063, p, 0.417) and BMISDS(r, À0.154, p, 0.087); and 13-18 years, with deceleration in HSDS(r, À0.383, p,<0.0001) and unchanged BMISDS(r, 0.015, p, 0.896).
Abstract G220 Aims Fasting blood tests (FBTs) are unnecessary and potentially dangerous in children. They may lead to hypoglycaemia and collapse, or delayed diagnosis of type 1 diabetes mellitus
